Extended Data Table 1.

Patient characteristics, clinical responses and adverse events

ASCT, autologous stem cell transplantation; B-LBL, B-cell lymphoblastic lymphoma; CR, complete remission; DLBCL, diffuse large B cell lymphoma; F, female; FL, follicular lymphoma; GCB, germinal center B cell; M, male; PR, partial remission. ^aAll prior lines of therapy for each patient are listed in Supplementary Table 6. None of the patients were treated with CAR-T cell therapy previously. ^bDisease was defined as refractory if a patient did not achieve partial or complete remission after the most recent chemotherapy. ^cBest response was defined as the best response that a patient achieved after CAR-T cell infusion. Response duration is the time from the first documentation of response, until disease progression, initiation of off-study treatment or the last documentation of ongoing response. The + symbol indicates an ongoing response.